JP2010502731A - Ｐａｒｐ阻害剤による脂肪酸合成の阻害、及びその治療方法 - Google Patents

Ｐａｒｐ阻害剤による脂肪酸合成の阻害、及びその治療方法 Download PDF

Info

Publication number
JP2010502731A
JP2010502731A JP2009527546A JP2009527546A JP2010502731A JP 2010502731 A JP2010502731 A JP 2010502731A JP 2009527546 A JP2009527546 A JP 2009527546A JP 2009527546 A JP2009527546 A JP 2009527546A JP 2010502731 A JP2010502731 A JP 2010502731A
Authority
JP
Japan
Prior art keywords
optionally substituted
fatty acid
administration
cancer
metabolite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009527546A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010502731A5 (enExample
Inventor
オソフスカヤ，バレリア
シャーマン，バリー
Original Assignee
バイパー サイエンシズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイパー サイエンシズ，インコーポレイティド filed Critical バイパー サイエンシズ，インコーポレイティド
Publication of JP2010502731A publication Critical patent/JP2010502731A/ja
Publication of JP2010502731A5 publication Critical patent/JP2010502731A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009527546A 2006-09-05 2007-09-05 Ｐａｒｐ阻害剤による脂肪酸合成の阻害、及びその治療方法 Pending JP2010502731A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84247906P 2006-09-05 2006-09-05
PCT/US2007/077662 WO2008030891A2 (en) 2006-09-05 2007-09-05 Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof

Publications (2)

Publication Number Publication Date
JP2010502731A true JP2010502731A (ja) 2010-01-28
JP2010502731A5 JP2010502731A5 (enExample) 2010-10-21

Family

ID=39158007

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009527546A Pending JP2010502731A (ja) 2006-09-05 2007-09-05 Ｐａｒｐ阻害剤による脂肪酸合成の阻害、及びその治療方法

Country Status (8)

Country Link
US (2) US7994222B2 (enExample)
EP (1) EP2061479A4 (enExample)
JP (1) JP2010502731A (enExample)
CN (2) CN101534836B (enExample)
AU (1) AU2007292306A1 (enExample)
CA (1) CA2662337A1 (enExample)
IL (1) IL197350A0 (enExample)
WO (1) WO2008030891A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016074741A (ja) * 2011-03-08 2016-05-12 ３−ブイ・バイオサイエンシーズ・インコーポレイテッド３−Ｖ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 脂質合成の複素環式モジュレーター
JP2020514747A (ja) * 2017-03-16 2020-05-21 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｋｒａｓ陽性癌の診断法及び治療法
US11622968B2 (en) 2011-03-08 2023-04-11 Sagimet Biosciences Inc. Heterocyclic modulators of lipid synthesis

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006257815A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. PARP modulators and treatment of cancer
EP1906948A4 (en) 2005-07-18 2010-03-17 Bipar Sciences Inc TREATMENT OF CANCER
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CA2655257A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
AU2007292306A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
WO2008030883A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
WO2008030892A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
WO2008030887A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
US7763601B2 (en) 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
CA2674600A1 (en) * 2007-01-16 2008-07-24 Valeria Ossovskaya Formulations for cancer treatment
WO2009051815A1 (en) * 2007-10-19 2009-04-23 Bipar Sciences, Inc. Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors
AU2008321382A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents
WO2009064738A2 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
AU2008333786A1 (en) * 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and PARP inhibitors
CA2713156A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
WO2010082813A1 (en) * 2009-01-13 2010-07-22 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Method of treating cancer
WO2010118324A2 (en) 2009-04-09 2010-10-14 Nuclea Biotechnologies, LLC Antibodies against fatty acid synthase
US8507195B2 (en) 2009-08-20 2013-08-13 The Regents Of The University Of Colorado MiRNAs dysregulated in triple-negative breast cancer
US8685891B2 (en) 2009-08-27 2014-04-01 Nuclea Biotechnologies, Inc. Method and assay for determining FAS expression
WO2012071562A2 (en) * 2010-11-24 2012-05-31 Gabrielle Ronnett Methods of screening compounds that are cytotoxic to tumor cells and methods of treating tumor cells using such compound
WO2012114204A2 (en) * 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
US9624173B2 (en) 2011-03-08 2017-04-18 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis
TWI522348B (zh) 2011-03-08 2016-02-21 ３ Ｖ生物科技公司 脂質合成之雜環調節劑
US8889707B2 (en) * 2012-02-08 2014-11-18 Malka COHEN-ARMON Treatment of addiction
KR102071095B1 (ko) 2012-07-03 2020-01-29 3-브이 바이오사이언시스, 인코포레이티드 지질 합성의 헤테로사이클릭 조절인자
MX364895B (es) 2013-03-13 2019-05-10 Forma Therapeutics Inc Nuevos compuestos y composiciones para la inhibicion de fasn.
CA2934251C (en) 2013-12-20 2024-01-02 3-V Biosciences, Inc. A combination of heterocyclic modulators of lipid synthesis and chemotherapeutic drugs in treatment of cancer
ES2833454T3 (es) 2014-08-15 2021-06-15 Sagimet Biosciences Inc Inhibidor de la ácido graso sintasa para su uso en el tratamiento de un cáncer farmacorresistente
JP6758314B2 (ja) 2015-03-19 2020-09-23 サギメット バイオサイエンシーズ インコーポレイテッド 脂質合成の複素環式調節因子
KR102644934B1 (ko) 2016-11-11 2024-03-08 새지메트 바이오사이언시스, 인코포레이티드 지질 합성의 헤테로사이클릭 조절인자
WO2018237327A1 (en) 2017-06-22 2018-12-27 Triact Therapeutics, Inc. Methods of treating glioblastoma
EP3687501A4 (en) 2017-09-29 2021-06-23 Triact Therapeutics, Inc. INIPARIB FORMULATIONS AND THEIR USES
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
CN110642890B (zh) * 2019-10-17 2022-02-01 常熟理工学院 化合物及其作为脂肪酸合酶活性探针上的应用
CN114751841B (zh) * 2022-05-31 2023-07-11 重庆文理学院 N-(3-(3-氯苯甲酰胺)苯基)-4-甲氧基-3-硝基苯甲酰胺及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510452A (ja) * 1993-05-12 1996-11-05 オクタマー，インコーポレイティド 抗ウイルス剤および抗腫瘍剤として有用な新規な芳香族ニトロおよびニトロソ化合物およびそれらの代謝物
JP2002502367A (ja) * 1997-05-13 2002-01-22 オクテイマー・インコーポレイテッド ｐＡＤＰＲＴインヒビターを用いる炎症および炎症性疾患の処置法
WO2006053748A1 (de) * 2004-11-20 2006-05-26 Bayer Healthcare Ag Substituierte [(phenylethanoyl)amino] benzamide und deren verwendung zur behandlung von inflammatorischen sowie herz-kreislauf-erkrankungen
WO2007011962A2 (en) * 2005-07-18 2007-01-25 Bipar Sciences, Inc. Treatment of cancer

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2669583A (en) 1954-02-16 X-amroo-zralkoxbbenzamdjes
US2006735A (en) 1932-11-17 1935-07-02 Gen Aniline Works Inc Nitro-aryl amino-aryl amines
NL247377A (enExample) 1957-11-25
US3161564A (en) 1960-10-03 1964-12-15 Salsbury S Lab Dr Veterinary composition containing halo-nitro-benzamides and methods of using same
US3228833A (en) 1962-12-17 1966-01-11 Sterling Drug Inc Anticoccidial compositions and methods of using same
AR204004A1 (es) 1973-04-02 1975-11-12 Lilly Co Eli Procedimientos para preparar derivados de vinblastina leurosidina y leurocristina
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5215738A (en) 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US5041653A (en) 1985-05-03 1991-08-20 Sri International Substituted benzamide radiosensitizers
US5032617A (en) 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
JP2534631B2 (ja) 1986-01-17 1996-09-18 プリベンティブ メディシン インスティテュート Ｄｎａが関連する病気にかかり易い体質または該病気に対する感受性を測定するための試験
US5283352A (en) 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US4923885A (en) 1988-08-19 1990-05-08 Merck & Co., Inc. 5-amino-1-(4-naphthoylbenzyl)-1,2,3-triazole-4-carboxamides and analogs as antiproliferative agents
JPH05503073A (ja) 1989-09-26 1993-05-27 オクタマー，インコーポレイテッド ウイルス性疾患の治療に有用な６―アミノ―１，２―ベンゾピロン
US5719151A (en) 1990-05-04 1998-02-17 Shall; Sydney Substituted benzene compounds
US5633282A (en) 1990-05-25 1997-05-27 British Technology Group Limited Inhibition of viral infection
US5637618A (en) 1990-06-01 1997-06-10 Bioresearch, Inc. Specific eatable taste modifiers
US5631038A (en) 1990-06-01 1997-05-20 Bioresearch, Inc. Specific eatable taste modifiers
US5232735A (en) 1990-06-01 1993-08-03 Bioresearch, Inc. Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers
DK0547165T3 (da) 1990-09-28 2000-03-27 Smithkline Beecham Corp Fremgangsmåde til fremstilling af vandopløselige camptothecinanaloger såvel som forbindelserne 10-hydroxy-11-C(1-6)-alkoxyc
US5484951A (en) 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
JPH06504791A (ja) 1991-04-10 1994-06-02 オクタマー，インコーポレイティド レトロウィルス複製の阻害のための方法
US5877185A (en) 1991-10-22 1999-03-02 Octamer, Inc. Synergistic compositions useful as anti-tumor agents
US5753674A (en) 1991-10-22 1998-05-19 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents, anti-retroviral agents and anti-tumor agents
US5482975A (en) 1991-10-22 1996-01-09 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
US5473074A (en) 1991-10-22 1995-12-05 Octamer, Incorporated Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents-54
US5516941A (en) 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5783599A (en) 1993-02-24 1998-07-21 Octamer Inc Methods of treating cancer and viral infections with 5-iodo-6-amino-and 5-iodo-6-nitroso-1 2-benzopyrones
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
US6015792A (en) 1993-05-26 2000-01-18 Bioresearch, Inc. Specific eatable taste modifiers
US6008250A (en) 1993-05-26 1999-12-28 Bioresearch, Inc. Specific eatable taste modifiers
GB9404485D0 (en) * 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
DK0841924T3 (da) 1995-08-02 2003-02-10 Univ Newcastle Ventures Ltd Benzimidazolforbindelser
US5837729A (en) 1996-04-26 1998-11-17 Metatron, Inc. Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof
US6017958A (en) 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US5736576A (en) 1996-06-04 1998-04-07 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
US20050287120A1 (en) 1997-03-21 2005-12-29 Fisher Paul B Cancer - targeted viral vectors
CA2285530A1 (en) 1997-03-26 1998-10-01 Biosource Technologies, Inc. Di-aryl ethers and their derivatives as anti-cancer agents
US5908861A (en) 1997-05-13 1999-06-01 Octamer, Inc. Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US6121278A (en) 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6235748B1 (en) 1997-09-03 2001-05-22 Guilford Pharmaceuticals Inc. Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US5922775A (en) 1997-10-23 1999-07-13 Octamer, Inc. Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity
US6380193B1 (en) 1998-05-15 2002-04-30 Guilford Pharmaceuticals Inc. Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
US6395749B1 (en) 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
JP2002515488A (ja) 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド カルボキサミド化合物、組成物、及びｐａｒｐ活性の抑制方法
CO5070700A1 (es) 1998-06-05 2001-08-28 Basf Ag Genes novedosos de (adp-ribosa) polimerasa
TR200101239T2 (tr) 1998-11-03 2001-11-21 Basf Aktiengesellschaft İkameli-2-fenilbenzimidazoller, üretimleri ve kullanımları
DK1133477T3 (da) 1998-11-27 2004-06-21 Abbott Gmbh & Co Kg Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
US6326517B1 (en) 1998-12-10 2001-12-04 Central Glass Company, Limited Method of producing benzamides
JP3552934B2 (ja) 1998-12-24 2004-08-11 セントラル硝子株式会社 安息香酸アミド類の製造方法
US6201020B1 (en) 1998-12-31 2001-03-13 Guilford Pharmaceuticals, Inc. Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
US6387902B1 (en) 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
EP1140936B1 (en) 1999-01-11 2004-03-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
KR20010101675A (ko) 1999-01-26 2001-11-14 우에노 도시오 2ｈ-프탈라진-1-온 유도체 및 그 유도체를 유효 성분으로하는 약제
US6423696B1 (en) 1999-04-16 2002-07-23 The United States Of America, As Represented By The Department Of Health & Human Services Inhibition of arylamine N-acetyl transferase
DE19921567A1 (de) 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US6277990B1 (en) 1999-12-07 2001-08-21 Inotek Corporation Substituted phenanthridinones and methods of use thereof
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
US6723733B2 (en) 2000-05-19 2004-04-20 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses
ITMI20002358A1 (it) 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
US20040053888A1 (en) 2001-01-04 2004-03-18 Norio Suzuki Cyclodextrin-containing pharmaceutical preparation
US20020142334A1 (en) 2001-01-30 2002-10-03 Brown Janice A. Methods of detecting poly(ADP-ribose) polymerase enzymatic activity
US20020164633A1 (en) 2001-04-20 2002-11-07 Inotek Pharmaceuticals Corporation Cell-based assay for detecting activation of poly (ADP-ribose) polymerase
WO2002090334A1 (en) 2001-05-08 2002-11-14 Kudos Pharmaceuticals Limited Isoquinolinone derivatives as parp inhibitors
KR100957516B1 (ko) 2001-08-15 2010-05-14 이코스 코포레이션 2ｈ-프탈라진-1-온 및 이것의 사용 방법
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
AUPS019702A0 (en) 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
AU2002335472B8 (en) 2002-03-26 2007-12-20 Banyu Pharmaceutical Co., Ltd. Combined use of antitumor indolopyrrolocarbazole derivative and other antitumor agent
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
EP1500643A4 (en) 2002-04-03 2007-03-28 Dainippon Sumitomo Pharma Co benzamidine
US20040034078A1 (en) 2002-06-14 2004-02-19 Agouron Pharmaceuticals, Inc. Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
JP2006508126A (ja) 2002-11-06 2006-03-09 アザヤ セラピューティクス インコーポレイティッド 薬学的製剤のタンパク質安定化されたリポソーム製剤
JP2006522088A (ja) 2003-03-31 2006-09-28 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤の塩
EP2365001A3 (en) 2003-05-01 2012-03-28 Imclone LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
EP1633362B1 (en) 2003-05-28 2012-09-26 Eisai Inc. Compounds, methods and pharmaceutical compositions for inhibiting parp
US20050004038A1 (en) 2003-06-27 2005-01-06 Lyon Robert P. Bivalent inhibitors of Glutathione-S-Transferases
MXPA06000993A (es) 2003-07-25 2006-08-31 Cancer Rec Tech Ltd Inhbidores triciclicos de parp.
KR20060054412A (ko) 2003-08-01 2006-05-22 와이어쓰 홀딩스 코포레이션 암 치료 및 억제용 표피 성장인자 수용체 키나제 억제제와세포독성제의 배합물 용도
WO2005023246A1 (en) 2003-09-04 2005-03-17 Aventis Pharmaceuticals Inc. Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp)
WO2005023765A1 (en) 2003-09-11 2005-03-17 Pharmacia & Upjohn Company Llc Method for catalyzing amidation reactions by the presence of co2
NZ546991A (en) 2003-11-20 2010-01-29 Janssen Pharmaceutica Nv 6-Alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as PARP inhibitors
NZ546990A (en) 2003-11-20 2010-03-26 Janssen Pharmaceutica Nv 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors
SG150548A1 (en) 2003-12-01 2009-03-30 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
JP4806353B2 (ja) 2003-12-05 2011-11-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ポリ（ａｄｐ−リボース）ポリメラーゼインヒビターとしての６−置換２−キノリノンおよび２−キノキサリノン
ES2565581T3 (es) 2003-12-10 2016-04-05 Janssen Pharmaceutica Nv 2-Quinolinonas/2-quinoxalinonas 6-(hetero)ciclohexilalquil sustituidas como inhibidores de poli(ADP-ribosa) polimerasa
US7439031B2 (en) 2003-12-15 2008-10-21 The Trustees Of The University Of Pennsylvania Method of identifying compounds that induce cell death by necrosis
US7680864B2 (en) 2004-03-02 2010-03-16 Intel Corporation Method and apparatus for managing access to stored objects based on retention policy
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
JP2005336083A (ja) 2004-05-26 2005-12-08 Sumitomo Chemical Co Ltd 芳香族アミノ化合物の製造方法
WO2006003147A1 (en) 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Phthalazine derivatives as parp inhibitors
JP5100376B2 (ja) 2004-06-30 2012-12-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐ阻害剤としてのキナゾリンジオン誘導体
CA2568835C (en) 2004-06-30 2014-05-27 Janssen Pharmaceutica N.V. Quinazolinone derivatives as parp inhibitors
US20060035890A1 (en) 2004-08-10 2006-02-16 Amit Banerjee Compounds and methods for the treatment of ubiquitin conjugating disorders
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
CA2581025C (en) 2004-09-22 2011-06-07 Pfizer Inc. Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
JP2008513435A (ja) 2004-09-22 2008-05-01 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
DE102004050196A1 (de) * 2004-10-15 2006-04-20 Sanofi-Aventis Deutschland Gmbh Substituierte 2-Pyridon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
WO2006046734A2 (ja) 2004-10-29 2006-05-04 Banyu Pharma Co Ltd オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
US20060094676A1 (en) * 2004-10-29 2006-05-04 Ronit Lahav Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
CN1768732A (zh) 2004-11-02 2006-05-10 上海富海科申药业有限公司 芳香硝基化合物在制备治疗肿瘤药物中的应用
CN1768733A (zh) 2004-11-02 2006-05-10 上海富海科申药业有限公司 芳香硝基化合物在制备治疗艾滋病药物中的应用
GB0428111D0 (en) 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
WO2006078503A2 (en) 2005-01-07 2006-07-27 Arqule, Inc. Compositions for modulation of parp and methods for screening for same
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
US7728026B2 (en) 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
AU2006257815A1 (en) 2005-06-10 2006-12-21 Bipar Sciences, Inc. PARP modulators and treatment of cancer
US20080293795A1 (en) 2006-01-17 2008-11-27 Abbott Laboratories Combination therapy with parp inhibitors
SI2338487T1 (sl) 2006-01-17 2014-01-31 Abbott Laboratories Kombinacijska terapija z inhibitorji PARP
CA2646156C (en) 2006-03-22 2016-05-24 Medigene Ag Treatment of triple receptor negative breast cancer
CA2655257A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20100160442A1 (en) 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
DE102006037399A1 (de) 2006-08-10 2008-02-14 Archimica Gmbh Verfahren zur Herstellung von Arylaminen
AU2007292306A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
WO2008030883A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
WO2008030887A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
WO2008030892A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
CN101190211B (zh) 2006-11-23 2011-08-10 上海富海科申药业有限公司 芳香硝基化合物在制备治疗病毒性肝炎药物中的应用
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
CA2674600A1 (en) 2007-01-16 2008-07-24 Valeria Ossovskaya Formulations for cancer treatment
JP5545955B2 (ja) 2007-03-08 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐおよびｔａｎｋ阻害剤としてのキノリノン誘導体
WO2009051815A1 (en) 2007-10-19 2009-04-23 Bipar Sciences, Inc. Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors
AU2008321382A1 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents
WO2009064738A2 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
AU2008333786A1 (en) 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and PARP inhibitors
CA2713156A1 (en) 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
AR075239A1 (es) 2009-02-04 2011-03-16 Bipar Sciences Inc Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510452A (ja) * 1993-05-12 1996-11-05 オクタマー，インコーポレイティド 抗ウイルス剤および抗腫瘍剤として有用な新規な芳香族ニトロおよびニトロソ化合物およびそれらの代謝物
JP2002502367A (ja) * 1997-05-13 2002-01-22 オクテイマー・インコーポレイテッド ｐＡＤＰＲＴインヒビターを用いる炎症および炎症性疾患の処置法
WO2006053748A1 (de) * 2004-11-20 2006-05-26 Bayer Healthcare Ag Substituierte [(phenylethanoyl)amino] benzamide und deren verwendung zur behandlung von inflammatorischen sowie herz-kreislauf-erkrankungen
WO2007011962A2 (en) * 2005-07-18 2007-01-25 Bipar Sciences, Inc. Treatment of cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6012050957; Ｒｅｃｅｎｔ　Ｐａｔ　Ｃａｒｄｉｏｖａｓｃ　Ｄｒｕｇ　Ｄｉｓｃｏｖ．，　１［２］　（２００６　Ｊｕｎ）　ｐ．１６７-７５． *
JPN6012050960; Ｃａｒｄｉｏｖａｓｃ　Ｒｅｓ．，　３６　（１９９７）　ｐ．２０５-２１５ *
JPN6012050963; Ｌｉｆｅ　Ｓｃｉ．，　７５　（２００４）　ｐ．１２５５-１２６１ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016074741A (ja) * 2011-03-08 2016-05-12 ３−ブイ・バイオサイエンシーズ・インコーポレイテッド３−Ｖ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 脂質合成の複素環式モジュレーター
US11622968B2 (en) 2011-03-08 2023-04-11 Sagimet Biosciences Inc. Heterocyclic modulators of lipid synthesis
US12551490B2 (en) 2011-03-08 2026-02-17 Sagimet Biosciences Inc. Heterocyclic modulators of lipid synthesis
JP2020514747A (ja) * 2017-03-16 2020-05-21 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｋｒａｓ陽性癌の診断法及び治療法

Also Published As

Publication number Publication date
AU2007292306A1 (en) 2008-03-13
US20120004260A1 (en) 2012-01-05
WO2008030891A2 (en) 2008-03-13
IL197350A0 (en) 2009-12-24
EP2061479A4 (en) 2010-08-04
CN102379884A (zh) 2012-03-21
US7994222B2 (en) 2011-08-09
WO2008030891A3 (en) 2008-08-21
CA2662337A1 (en) 2008-03-13
EP2061479A2 (en) 2009-05-27
CN101534836A (zh) 2009-09-16
US20080103208A1 (en) 2008-05-01
CN101534836B (zh) 2011-09-28

Similar Documents

Publication Publication Date Title
US7994222B2 (en) Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds
El Hout et al. Crosstalk between autophagy and metabolic regulation of cancer stem cells
Zhang et al. Histone lactylation bridges metabolic reprogramming and epigenetic rewiring in driving carcinogenesis: Oncometabolite fuels oncogenic transcription
Kahlert et al. Targeting cancer stem‐like cells in glioblastoma and colorectal cancer through metabolic pathways
JP2025102814A (ja) 発毛を調節するための組成物及び方法
Rashmi et al. Glutaminase inhibitors induce thiol-mediated oxidative stress and radiosensitization in treatment-resistant cervical cancers
CN101888777A (zh) 用拓扑异构酶抑制剂和parp抑制剂的组合治疗癌症
JP6401317B2 (ja) がんを治療するためのシステム、方法、および製剤
Li et al. Cuproptosis in lung cancer: mechanisms and therapeutic potential
Ambrosini et al. Transcending frontiers in prostate cancer: the role of oncometabolites on epigenetic regulation, CSCs, and tumor microenvironment to identify new therapeutic strategies
JP2018529742A (ja) Ｅｚｈ２阻害剤を用いた髄芽腫の処置方法
Mendes et al. Revisiting lactate dynamics in cancer—a metabolic expertise or an alternative attempt to survive?
CA2715036A1 (en) Therapies for cancer using isotopically substituted lysine
WO2012035747A1 (ja) がん温熱療法の作用増強剤
Chen et al. Mechanism, clinical significance, and treatment strategy of Warburg effect in hepatocellular carcinoma
Liang et al. The promise of mitochondria in the treatment of glioblastoma: a brief review
Yang et al. Crosstalk between ferroptosis and endoplasmic reticulum stress: A potential target for ovarian cancer therapy
Zhou et al. BCAA metabolism in cancer progression and therapy resistance: The balance between fuel and cell signaling
Bononi et al. A patent review of lactate dehydrogenase inhibitors (2014–present)
Zhao et al. Exploring the role of ferroptosis in esophageal cancer: mechanisms and therapeutic implications
Yu et al. Dual role of lactate in ferroptosis: Mechanisms, pathophysiology and therapeutic opportunities
Malhotra et al. Metabolic shifts in glioblastoma: unraveling altered pathways and exploring novel therapeutic avenues
US11684601B2 (en) Treatment of cancer with combinations of agents
AU2014398232A1 (en) Pharmaceutical compounds
JP6395724B2 (ja) 医薬化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121107

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121114

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130611